An update of ALK inhibitors in human clinical trials
- Eason Leong Yin Chan,
- Claudia Ho Yi Chin,
- Vivian Wai Yan Lui(corresponding author)
- The University of Hong Kong
Scholary Output:
Contribution to journal
Review article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>The proto-oncogenic ALK is a druggable receptor tyrosine kinase for cancer treatment. Two small molecule inhibitors of ALK, crizotinib and ceritinib, have been recently approved for the treatment of metastatic non-small-cell lung cancer, with marked improvement of progression-free survival of patients. Independent case reports also indicate their potential therapeutic activity in other ALK-rearranged cancers. Numerous single-agent and combination therapy trials are ongoing in lung and many other cancers. Results of these trials are greatly anticipated. Here, we summarize our current understanding of ALK signaling, genomic aberrations in cancer and emerging mechanisms of drug resistance. We will also provide a timely review on all ALK inhibitors and their current status of development in clinical settings.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Review article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 71-81 (11 pages)Journal (Volume, Issue Number)
Future Oncology (Volume 12, Issue 1)Publication milestones
- Published - 01/2016
Publication status
Published - 01/2016
ISSN
1479-6694Publication IDs
- Scopus: 84952066272
- PubMed: 26618223
Publication metrics
Metrics
Fractional count
1
Fractional count
0.33
Fractional count
2
Fractional count
0.67
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
10
Captures
19
